Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evaluation of Cell-penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination

Version 1 : Received: 15 June 2021 / Approved: 16 June 2021 / Online: 16 June 2021 (10:19:31 CEST)

How to cite: Lobaina, Y.; Urquiza, D.; Garay, H.; Perera, Y.; Ke, Y. Evaluation of Cell-penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination. Preprints 2021, 2021060431 (doi: 10.20944/preprints202106.0431.v1). Lobaina, Y.; Urquiza, D.; Garay, H.; Perera, Y.; Ke, Y. Evaluation of Cell-penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination. Preprints 2021, 2021060431 (doi: 10.20944/preprints202106.0431.v1).

Abstract

Cell-penetrating peptides (CPPs) have been evaluated as enhancers in drug delivery, their addition in medical formulations favors absorption allowing obtaining the pharmacological effect with lower drug doses. In vaccine formulations their inclusion has been also explored with interesting results. Currently mucosal vaccination constitutes a promising alternative with the main advantage of inducing both systemic and mucosal immune responses, which are crucial for control tumors and infections at mucosal tissues. The known CPP Penetratin was recently evaluated in vaccine formulations designed for nasal administration. The authors demonstrated that this non-covalent linked CPP could improve the antigen-specific systemic and mucosal antibody responses. In the present work we evaluate in Balb/C mice the nasal immune-enhancing effect of four CPPs. Animals were intranasally immunized with CPP and the recombinant hepatitis B surface protein (HBsAg) as model antigen. The IgG antibody response in sera and the mucosal IgA response were measured by ELISA. The IFN-g secretion response at spleen was also evaluated by ELISPOT and ELISA. Among the CPPs studied one novel peptide stand out by its ability to potentiate the humoral and cellular immune response against the co-administered antigen. Considering that the use of mucosal routes is a promising strategy in vaccination against infectious diseases and cancer, which are gaining special relevance nowadays in the development of novel candidates against SARS-CoV-2 and other potential emerging respiratory virus, the searching and development of safe mucosal adjuvants constitute a current need.

Subject Areas

cell-penetrating peptides; nasal vaccination; mucosal; immune enhancer; adjuvant

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.